β¨ Medicine Distribution Consents
NEW ZEALAND GAZETTE
No. 81
2148
Product:
Apo-Famotidine
Active Ingredient:
Famotidine 20mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Weston, Ontario, Canada
Product:
Apo-Famotidine
Active Ingredient:
Famotidine 40mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Weston, Ontario, Canada
Product:
Apo-Mefenamic
Active Ingredient:
Mefenamic acid 250mg
Dosage Form:
Capsule
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Weston, Ontario, Canada
Dated this 12th day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4754
Consent to the Distribution of a Changed Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:
Schedule
Product:
Glivec
Active Ingredient:
Imatinib mesylate 119.5mg equivalent to 100mg imatinib base
Dosage Form:
Capsule
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Note: This product has consent that expires on 18 October 2003.
Product:
Glivec
Active Ingredient:
Imatinib mesylate 59.75mg equivalent to 50mg imatinib base
Dosage Form:
Capsule
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland
Note: This product has consent that expires on 18 October 2003.
Dated this 10th day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4751
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:
Schedule
Product:
Visudyne
Active Ingredient:
Verteporfin 15mg
Dosage Form:
Powder for infusion
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturers:
Parkedale Pharmaceuticals Inc, Rochester, Michigan, United States of America
S P Pharmaceuticals (Subsidiary of R P Scherer West Inc), Albuquerque, New Mexico, United States of America
Dated this 10th day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4752
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 81
Gazette.govt.nz —
NZ Gazette 2002, No 81
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of New Medicines
(continued from previous page)
π₯ Health & Social Welfare12 July 2002
Medicines Act 1981, New Medicines, Apo-Famotidine, Famotidine, Apo-Mefenamic, Mefenamic acid, Apotex NZ Limited, Apotex Inc
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare10 July 2002
Medicines Act 1981, Changed Medicine, Glivec, Imatinib mesylate, Novartis New Zealand Limited, Novartis Pharma Stein AG
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare10 July 2002
Medicines Act 1981, Changed Medicine, Visudyne, Verteporfin, Novartis New Zealand Limited, Parkedale Pharmaceuticals Inc, S P Pharmaceuticals
- G. R. Boyd, Chief Advisor, Safety and Regulation